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SUMMARY - We prospectively surveyed 23 pregnant women with epilepsy on lamotrigine
monotherapy and reported outcome oftheir pregnancies, including one fetal intrauterine death, one
spontaneous abortion and two preterm deliveries. There were no congenital malformations in their
offspring. Women with pregnancy planning and folic acid intake delivered babies with higher values
ofbirth weight and birth length. There was large inter-patient variation during drug monitoring and
in the need of dose adjustment. Individual approach to every woman and monotherapy with mini-
mal effective lamotrigine dose with frequent drug monitoring enhances the possibility for successful
pregnancy. The management ofwomen with epilepsy should begin with pre-pregnancy counseling.
Planned pregnancy enables periconceptional folic acid supplementation. Despite the small number
of cases, these data indicate that la motrigine treatment during pregnancy might be relatively safe.
Larger prospective studies are needed to obtain adequate power for statistical analysis including
long-term cohort studies.
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Introduction
Women with epilepsyare at a greater risk ofcomplica-
tions in pregnancy, labor and adversepregnancy outcomes
than women without epilepsy. Teratogenic effects of all
commonly used antiepileptic drugs (AEDs) in pregnan-
cy have been recognized but relative risks of new AEDs
and their long-term neurodevelopmental effects remain
poorly understood. Some of the newer AEDs have not
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been used in large enough numbers to have meaningful
data. In general, AED polypharmacy and higher blood
levelsof AEDs are associatedwith an increased incidence
of birth defects in infants born to women with epilepsy.
A single AED at the lowest possible dose for efficacy is
recommended whenever possible'.
All live-born children have 2-4 percent of risk to
be born with some major malformation, but in women
with epilepsy on one AED the incidence is 4-8 per-
cent'. Methods of prenatal diagnostic testing offered
to women with epilepsy should include measurement
of maternal serum a-fetoprotein and level II fetal ul-
trasonography or amniocentesis, if warranted.'. Major
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malformations most often found in children born to
women with epilepsy are orofacial clefts, cardiac abnor-
malities and neural tube defects. Periconceptional folic
acid supplementation may minimize the risk of neural
tube defects in their offspring:'.
In many countries, national registries are being
formed in order to collect new information on the pos-
sible teratogenicity of newer AEDs such as lamotrigine
(LTG). The Australian Registry collected 68 pregnan-
cies exposed to LTG and another AED and reported 3
childrenwith different anomalies'. The North American
AED Pregnancy Registry enrolled 564 women on LTG
monotherapy during the first trimester ofpregnancy: 15
newborns with malformations,S with cleft lip. Out of
1623 children exposed to LTG in another 5 registries,
4 had cleft palate or cleft lip (1:405 or 2.5/1,000) com-
pared to 0.37/1,000 in the control group. These cases
offered first information on the possible significant risk
of cleft lip in children at in utero LTG exposures.'. The
UK Epilepsy and Pregnancy Register found 3.2% of
major malformations from pregnancies on LTG; facial
clefts were found in 0.2%, like in general population.
The pregnancies exposed to LTG doses above 200 mg
resulted in 5.4% of major congenital malformations'.
Dolk et al. found no evidence of a specific increased
risk of isolated orofacial clefts relative to other malfor-
mations due to LTG monotherapy among 3.9 million
births from 19 registries 1995-20058 In their human
pregnancy registry study, Cunnington and Tennis re-
port that among 414 first-trimester exposures to LTG
monotherapy, 12 (2.9%) cases presented with major
birth defects, with no distinctive pattern of major birth
defects being apparent among the offspring exposed to
LTG monotherapy or polytherapy". The Neurodevel-
opmental Effects of Antiepileptic Drugs Prospective
Study found 1% of malformations in 98 mothers on
LTGIO Until September 2007, the Lamotrigine Preg-
nancy Registry prospectively enrolled 1155 outcomes of
pregnancies on LTG monotherapy: there were 2.7% of
various major malformations, no association between
LTG daily dose of400 mg and frequency of malforma-
tions, and no higher incidence of orofacial clefts".
A greater incidence of mental retardation and/or
microcephaly has been reported in children born to
women with epilepsy or on particular type ofAED, but
these studies were inconsistent':'. Factors other than
maternal epilepsy that are thought to be important are
maternal IQ.scores and AED polypharmacy (particu-
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larly in utero exposure to methvlphenobarbitone)'. There
is no increased risk of early fetal death in women with
epilepsy. Late fetal loss (stillbirth or spontaneous abor-
tion after 20 weeks of pregnancy) shows an increased
incidence in women with epilepsy, as much as twofold
that in general population'.
Good seizure control protects both the mother and
the fetus. During pregnancy, one quarter to one third
of women with epilepsy have an increase in seizure
frequency despite continued use of AEDs. Decreased
protein binding of AEDs, increased drug clearance,
and increased maternal plasma volume during preg-
nancy may lower serum concentrations of AEDs. In
the majority of pregnancies, there is a need for increase
ofLTG dosage and adjustment to previous dosage after
delivery13-1s.
A favorable outcome of pregnancy in women with
epilepsy on antiepileptic therapy can be achieved by
pregnancy planning and preconception counseling in-
volving a team ofexperts consisting ofa neurologist, gy-
necologist, geneticist, etc. The preconception counsel-
ing, as a continuous process of planning and preparing
for pregnancy and gaining optimal balance of physical,
emotional and mental health before conception, could
be one of the predictors of favorable outcome in such
pregnancies.
Croatia is a Mediterranean European country with
4 million inhabitants. Since the foundation of two in-
stitutions in our country, Teratogen Information Ser-
vice Zagreb (TIS Zagreb) and Center for Counseling
in Epilepsy and Pregnancy in the year 2003, prospec-
tive data on pregnant women with epilepsy have started
to be recorded systematically at our hospital based reg-
istry with the aim to establish safety of AEDs during
pregnancy that are marketed in Croatia.
This was a prospective study designed to follow-up
pregnancies in Croatian women with epilepsy treated
with LTG and their offspring in order to provide ad-
ditional data on the teratogenic risk of LTG and to
assess the effects of preconception counseling in such




All pregnant women were recruited for the study
from the Center for Counseling in Epilepsy and Preg-
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nancy, University Department of Neurology, Sestre
milosrdnice University Hospital, during a 5-year period
(May 2003 - May 2008). Our Center has a multidis-
ciplinary team of medical professionals - neurologists,
gynecologists, pediatricians and genotoxicologist. All
women were enrolled in the study in the first trimester
of pregnancy. Most of them had been surveyed at the
same hospital before their index pregnancies occurred,
and one third presented for the first time in the Cen-
ter for Counseling during pregnancy. All study women
were surveyed prospectively during their pregnancy and
all were taking LTG throughout pregnancy. All new-
borns were examined and followed-up to at least one
year of age by neuropediatricians and clinical geneticists
at University Department of Pediatrics in the same hos-
pital. All pregnant women with epilepsy were controlled
by a gynecologist in the same hospital and delivered at
Maternity Unit, Sestre milosrdnice University Hospital.
This survey was the first phase of an ongoing pro-
spective study in Croatia including pregnant women
with epilepsy treated with all types of AEDs and
long-term follow up of their offspring till school age
in order to assess long-term neurodevelopmental ef-
fects of newer AEDs.
Study population
A total of 23 pregnancies under LTG monother-
apy were enrolled during the period of 5 years (May
2003 - May 2008). The data obtained from pregnant
women included their age, history of previous abor-
tions or children with congenital malformations, par-
ity, type and duration of epilepsy, and types and doses
ofAEDs before pregnancy. Data on current pregnan-
cy included information on pregnancy planning, peri-
conceptional folic acid intake, frequency of seizures,
and adjustment ofAED doses during pregnancy with
final outcome of pregnancy. The data collected after
pregnancy included adjusted AED doses, if needed.
The 'periconceptional' folic acid intake in women
with epilepsy referred to folic acid intake at least 4
weeks before pregnancy and during pregnancy. The
term 'pregnancy planning' refers to the woman's deci-
sion to achieve pregnancy and consideration of chang-
ing dietary habits prior to conception.
The information collected on newborns included
gestational weeks at delivery (Farr evaluation), Ap-
gar score, birth weight and birth length, neuropedi-
atric evaluation and detailed clinical examination by
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clinical geneticist in order to exclude major and minor
congenital malformations. Further investigations, if
needed, included brain ultrasound, karyotyping, car-
diologic evaluation, etc.
All live births were prospectively surveyed by two
hospital neuropediatricians till the first year of life in
order to exclude other possible congenital malforma-
tions (some congenital heart malformations, genito-
urinary tract malformations) and neurodevelopmental
effects of AEDs.
Statistical analysis
Data were presented as mean ± standard devia-
tion (SD). Due to the small sample size, comparisons
between the means of values from pregnancies with
favorable outcome and pregnancies with adverse out-
comes and between the means of values in pregnant
women with and without folic acid supplementation
were made by use of two-tailed Student's z- test. A




During the 5-year period (May 2003 - May 2008),
23 Croatian pregnant women with epilepsy on LTG
monotherapy were enrolled. Pregnant women were
all Caucasians, with no ethnic differences. The mean
age of women with epilepsy was 27.14±3.15 years.
Of 23 women, only 4/23 had graduated at university,
while most of them (17123) had medium educational
level (secondary school) and 2123 had low educational
level (elementary school). Most of them were mar-
ried (22123), with average family income (19123). In
11123 women it was the first pregnancy, 3123 had
previous spontaneous abortions, and none had a child
with congenital malformation (Table 1). Eleven of 23
women planned their pregnancies and 16 took folic
acid during the periconceptional period. Four women
were smoking throughout pregnancy and they all de-
livered healthy newborns. None of the study women
reported alcohol consumption.
Drug monitoring during pregnancy
Seventeen of 23 women with epilepsy under LTG
had favorable outcome of pregnancy and delivered
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Table 1. Sociodemographic/reprodudive characteristics,
pregnancyplanning andfolic acid supplementation in
women with epilepsy on lamotrigine therapy
df-Sz, standard error of difference = 16.516) and also
slight, statistically non-significant differences in the
mean percentage of dose readjustments after preg-
nancy (24% vs. 7%) (P=0.0935). The majority of LTG
doses after pregnancy needed to be readjusted dur-
ing 8 weeks after pregnancy, but the values of LTG
still remained higher than those before pregnancy.
The mean daily dose of LTG during pregnancy in 6
women with adverse pregnancy outcome was 188 mg
and after pregnancy 150 mg.
The maximal daily LTG dose of 400 mg during
pregnancy was the same in both groups of women
with epilepsy, but there were differences in maxi-
mal LTG doses during pregnancy between the two
groups. Most pregnant women with adverse outcome
did not cross the preferred LTG daily dose of200 mg,
whereas even 7/17 women with favorable outcomes
did.
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Fig. 1. Adjustment 0/daily lamotrigine (LTG) doses in
women withfavorable and adversepregnanry outcomes
healthy newborns. In 4 of these 17 patients, A ED
had been switched to LTG short before pregnancy,
whereas 13 women had been treated with LTG for a
longer period before pregnancy.
In the group of women with favorable pregnancy
outcome, the mean daily dose of LTG before preg-
nancy was 135 mg (range 25-300), during pregnancy
200 mg (range 50-400), and after pregnancy 141 mg
(range 50-300). Adjustment ofthe daily dose of LTG
was required in 13/17 patients, andin 10 of them more
than once during pregnancy. The LTG dose adjust-
ment was mostly done during 4th and 5th gestational
month: for seizures accompanied by low plasma LTG
concentration during pregnancy in 8 women and for
low LTG concentration in another 5 women. Data on
LTG dose adjustments during and after pregnancies
in study women are presented in Fig. 1. These data
reflect the high inter-individual variability in the need
for dose adjustment among all women. Dose adjust-
ment was mostly required between 4th and 5th gesta-
tional month. Six women with adverse outcomes are
presented on Fig. 1 with dashed lines, and 4 of them
with almost linear dashed lines. Due to the short
duration of their pregnancies, there was no need for
adjustment of LTG dose. The same reason could ex-
plain the slight, but not statistically significant dif-
ferences in the mean percentage of dose adjustment
during pregnancy between women with favorable out-
come and those with adverse outcome (47% of previ-
ous dose in women with favorable outcome vs. 24% of
previous dose in women with adverse pregnancy out-
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Table 2. Outcome ofpregnancies with antiepileptic drug (AED) therapy switch short beforepregnancy
Patients
AED Max LTG Max Pregnancy
with Seizure Outcome
epilepsy
before during LTG after planninglFA
deterioration
N~7
pregnancy pregnancy pregnancy intake
1 VPA 300 200 YeslYes Yes Live birth
2 PHT 100 100 YeslYes No Live birth
3 CBZ 250 200 NolYes No Live birth









6 VPA 125 125 YeslYes No in 7th week,
toxoplasmosis
7 TPM 125 100 NolYes No Live birth
VPA, valproic acid; PHT, phenytoin; CBZ; carbamazepine; MPB, methylphenobarbitone, TPM, topiramate
Seven women were treated with other types of
AED short before pregnancy: 3 with valproic acid
(VPA), another 3 with monotherapy including topi-
ramate (TPM), phenytoin (PHT) and carbamazepine
(CBZ), and 1 with CBZ and methylphenobarbitone
(MPB) (Table 2). In all of them, the previous AED
therapy was switched to LTG short before pregnancy.
Two of them had seizures during pregnancy and half













1 LTG 150 275 175 Live birth
2 VPA 300 200 Live birth
3 LTG 200 225 200 Live birth
4 LTG 75 125 50 Live birth
5 CBZ+MPB 400 250
Preterm delivery, somatic
hypotrophy
6 LTG 150 175 150
Preterm delivery,
Apgar 7/8
7 LTG 100 125 100 Live birth
8 LTG 225 400 300 Live birth
AED, antiepileptic drug; LTG,lamotrigine; VPA, valproic acid; CBZ; carbamazepine;MPB,
methylphenobarbi tone
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of pregnancies were planned. Four of these 7 wom-
en had adverse outcomes of pregnancies versus 2/16
women that had been already treated with LTG for a
longer period before pregnancy.
Eight women had seizures during pregnancy,
but they all delivered live-births (Table 3). The only
adverse outcomes in the group with seizures were 2
preterm deliveries: one child was healthy and another
one, with Apgar 7/8, had moderate neurodevelop-
mental delay during follow up, but was successfully
rehabilitated in our hospital. These two women with
pre term deliveries did not have higher frequency of
seizures than another six women with seizures that
delivered on term.
In 23 study women, there was no case of maternal
toxicity due to higher plasma concentration of LTG.
Pregnancy planning and periconceptional folic acid
intake
Nine of 17 women with favorable outcome planned
their index pregnancies, but due to preconception
counseling and repeated recommendations for folic
acid intake during therapy with AEDs, even 13/17
women took folic acid during proper periconcep-
tional period. Women with folic acid intake deliv-
ered babies with significantly higher values of birth
weight than those without folic acid supplementation
(P=0.0066, t=3.1472, df-lS, standard error of differ-
ence = 226.7S6), and also significantly higher values
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of birth length (P=0.0409, t=2.2367, df-lS, standard
error of difference = 0.748). There was no statistical
significance for gestational weeks between the two
groups (P=0.3791, t=0.9064, df=IS, standard error of
difference = 0.382) (Table 4).
In 6123 women, the outcome of pregnancy was ad-
verse (Table S): one had elective termination of preg-
nancy because of spontaneous abortion just before the
index pregnancy and unplanned index pregnancy; one
had intrauterine fetal death in 20,h week without evi-
dence of infection, genetic disease or congenital mal-
formation; 2 had spontaneous abortion, but one of
them was diagnosed with Toxoplasma infection. There
were also 2 preterm deliveries, mentioned before in the
group of women with seizures. Halfof the women with
adverse outcome took folic acid periconceptionally.
Upon exclusion of one spontaneous abortion due
to Toxoplasma infection and one elective termination
of pregnancy, we recorded 1 spontaneous abortion and
2 preterm deliveries among 23 women with epilepsy.
In this prospective surveillance, no congenital mal-




planning and folic acid intake
In 2003, we conducted a survey in S69 Croatian
women with low risk pregnancies in order to assess
Table 4. Clinicalparameters ifneonates born to mothers with favorable outcome
according topregnancy planning andfolic acid intake







Favorable - not planned
and FA not taken 38.50 0.58 49.25 0.96 2892.50 378.71
n~4
Favorable - planned
and FA taken 38.84 0.69 50.92 1.38 3606.15 400.93
n~13
All favorable
pregnancies 38.76 0.66 50.53 1.46 3438.24 480.02
n~17
GW,gestational weeks; BL, birth length; BW, birth weight; FA, folic acid; SD, standard deviation
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TableS. Women with adversepregnancy outcomes (N=6)
Surveillance of pregnancies on Iamotrtgtne
Patients AED Max LTG Max
with before during LTG after
Pregnancy outcome
Pregnancy Folic acid
epilepsy pregnancy pregnancy pregnancy planning intake
N=6 rug/day mglday rug/day







3 LTG 150 175 150 Preterm delivery,Apgar 7/8 No Yes
4 LTG 25 100 100
Spontaneous abortion at 5
No No
gestational weeks
5 VPA 150 150 Fetal intrauterine death No No
6 VPA 125 125
Spontaneous abortion at 7
Yes Yes
gestational weeks (toxoplasmosis)
AED, antiepileptic drug; LTL, Iamotrtgtne; CBZ, carbamazepine; MPB, methylphenobarbitone; VPA, valproic acid
the proportion of pregnancy planning in Croatia and
periconceptional folic acid intake in low risk preg-
nancies": Comparison of data on these women with
low risk pregnancies and our women with epilepsy
yielded a lower proportion of high level of education
in women with epilepsy, whereas proportions in the
values of marital status, family income, parity and
previous spontaneous abortions were the same. Half
of the women with epilepsy planned their pregnancy
compared to 75% of planned low risk pregnancies in
Croatia, but even 16/23 of women with epilepsy took
folic acid properly compared to only 14% of women
with low risk pregnancies. Gjergja et al. found statisti-
cal significance for higher educational level and fam-
ily income with folic acid awareness and intake": In
this group ofwomen with epilepsy proper preconcep-
tion counseling was crucial for the high proportion of
periconceptional folic acid intake. They had received
counseling about the benefits of long-term folic acid
supplementation in case ofAED therapy. The effect of
the addition of folic acid to LTG therapy was inves-
tigated by Ali et al.17 They concluded that the com-
bination of LTG and folic acid significantly reduced
depression, while enhancing the effects on memory
and seizure threshold at the same time. LTG does not
affect the seizure and memory threshold. LTG is a di-
hydrofolate reductase inhibitor, and it decreases fetal
folate levels in rats. Nevertheless, while LTG therapy
has not been associated with significant changes in
Acta Clin Croat, Vol. 48, No.3, 2009
serum folate, periconceptional folic acid supplementa-
tion is recommended".
In their case-control study, Palma et al. found no
correlation between folic acid only (15 mg/day) and
low birth weight (LBW), whereas iron supplemen-
tation (80 mg ferrous sulfate) was associated with a
lower risk of LBW (odds ratio (OR) 0.58, 95% CI
0.34-0.98), adjusted for smoking, maternal education,
body mass index, obstetric diseases during pregnancy,
weight gain during pregnancy, and previous LBW9
Neither vitamin B12 nor folate concentrations in all
three trimesters showed any significant associations
with birth weight in a study by Takimoto et al.20
Newborns in our study had very significantly
higher values of BW in the group of mothers with
epilepsy, planned pregnancy and folic acid intake. Be-
cause of the small sample size and no adequate power
of statistical analysis, we can only assume that the
better pre/pregnancy care, pregnancy planning and
folic acid intake influenced better results in anthro-
pometric measures of newborns in our study. As this
was a prospective study and only a part of a bigger
prospective surveillance in Croatian pregnant women
with epilepsy, we will draw final conclusions after get-
ting larger sample size and control group.
Drug monitoring during pregnancy
The mechanisms of action of LTG have not yet
been full understood and there are few hypotheses:
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from the possibility that LTG inhibits synaptic re-
lease of glutamate by acting on Na+ channels'!, to
interfere with neuronal sodium channels and inhibit
the release of excitatory amino acids, glutamate and
aspartatev', or to decrease glutamate release": LTG is
metabolized primarily by glucuronidation.
Today, neurologists rely on clinical parameters and
on monitoring drug concentration in plasma in order
to administer an LTG dosage that would be within
the therapeutic limits. Obviously, it is not always easy
to achieve in pregnant patients. Petrenaite et al. ret-
rospectively reviewed 11 pregnant women on LTG
monotherapy and observed a significant decrease in
the plasma LTG concentration-to-dose ratio (65.1%)
during second trimester (P=0.0058); it was followed
by a 65.8% decrease during third trimester (P=0.0045)
compared to pre-pregnancy values. Five patients ex-
perienced seizure deterioration during pregnancy.
The pharmacokinetic changes displayed inter-patient
variation.". In our group of women, there was also
marked inter-patient variation, stressing the need of
evaluating each woman individually by closely moni-
toring LTG concentrations until full term and at least
8 weeks afterwards. Harden concludes that LTG lev-
els can be expected to decline by 65%-90% during
pregnancy>.
Patients should be monitored carefully during
pregnancy, both clinically and by serum levels. De
Haan et al. also suggest that frequent LTG level
monitoring and appropriate dose adjustments are ad-
vised in the periods before and during pregnancy, as
well as after delivery, especially in women on LTG
monotherapy". Frequent LTG dose readjustments
in our study demanded full women's compliance and
cooperation. Adab suggests that changes in LTG
clearance are particularly marked, with increases in
each trimester and a significant fall in plasma con-
centrations, leading to subsequent breakthrough sei-
zures in some women.". From our experience, there
is no way to know which woman will have seizures
and in which period of pregnancy, even by frequent
measuring plasma LTG concentrations. Out of 15 our
women that needed LTG adjustment, 8 had seizure
deterioration during pregnancy. LTG concentrations
may also rise after delivery, leading to symptoms of
toxicity'S Regular drug monitoring has been advo-
cated in each trimester and shortly after delivery, with
appropriate adjustment of dosage to avoid seizure pre-
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cipitation during pregnancy or symptoms of toxicity
after delivery. Frequent monitoring has been recom-
mended for LTG29. We suggest that the frequency of
drug monitoring should also be individually adjusted
to each woman. Some of our women needed drug
monitoring every week because of seizures and fre-
quent changes in LTG concentrations, whereas some
others were monitored once in each trimester. In our
surveillance we wanted to put emphasis not on plasma
LTG concentrations, but on the mean and maximal
doses in women with epilepsy, in order to point to the
clinician how high the LTG dose should be to have
the plasma LTG concentration within the therapeutic
range.
In our series of pregnant women, there was no ef-
fect of dose, up to 400 mg/day, on the adverse out-
come of pregnancy. The same has been reported by
Cunnington et al. who analyzed data from the Inter-
national Lamotrigine Pregnancy Registry in order to
examine the effect of maximal first-trimester mater-
nal dose of LTG monotherapy on the risk of major
birth defects. The distribution of dose did not differ
between infants with and those without birth defects.
A logistic regression analysis showed no difference in
the risk of MBDs as a continuous function of dose.
There was no effect of dose, up to 400 mg/day, on the
frequency of birth defects either'S
Data from human studies indicate that LTG
crosses the placenta. Ohman et al. report on a decrease
in plasma level of LTG as pregnancy progressed.".
The dose to plasma concentration ratio was 5.8 times
higher at delivery and 3.6 times higher in late preg-
nancy. Castel-Branco et al. report that LTG plasma
levels may be good indicators of LTG levels in the
brain, and that higher response intensities could be
expected with higher doses of LTG, since efficacious
concentrations are maintained for a longer period".
Johannessen and Tomson suggest that, for the newer
AEDs that are metabolized (felbamate, LTG, oxcar-
bazepine, tiagabine and zonisamide), pharmacoki-
netic variability is just as relevant as for many of the
older AEDs. Therefore, therapeutic drug monitoring
is likely to be useful in many clinical settings for the
newer AEDs31
Clinicians involved in antiepileptic therapy of
pregnant women should be aware of inter-individual
differences in the kinetics of LTG among pregnant
women. This variability is considered to be the conse-
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quence of other drug intake, age, body habitus, smok-
ing, comorbidity, etc. Recently, the genetic polymor-
phism ofUDP glucuronosyltransferase lA (UGTIA)
is considered to be one of the main reasons for individ-
ual diversity ofLTG kinetics during pregnancy13.24.2S
The proportions of higher clearance of LTG during
pregnancy are very likely a reflection of the specific
metabolic pathway of LTG, glucuronidation and in-
fluence of steroids from the ovary. Ohman et al. ana-
lyzed LTG metabolites during pregnancy and found
an increased 2N glucuronide/lamotrigine ratio dur-
ing pregnancy. It points to the increased metabolism
of LTG because of glucuronidation32 Additional
research into the impact of pregnancy on LTG me-
tabolism is necessary, along with further study of the
pharmacokinetics and pharmacodynamics of LTG in
pregnancy.
If the woman with epilepsy is treated with a poten-
tially teratogenic AED, it is desirable to switch it to
LTG or some other AED before planned pregnancy.
Our group of seven women with therapy switch 10
days to 1 month before index pregnancy had 2 adverse
outcomes: one fetal intrauterine death and one pre-
term delivery. Considering these results, it would be
wise to wait with pregnancy for at least 2 months after
therapy switch. In the group of women with favor-
able outcome, 4 hadAED therapy switch to LTG, but
more than 6 months before the index pregnancy.
Conclusion
Croatian pregnant women with epilepsy on LTG
monotherapy demonstrated high awareness of preg-
nancy planning and folic acid intake. Considering our
series ofwomen with epilepsy, LTG can be the AED
of choice in epilepsy treatment during pregnancy.
Classic AED could be replaced with LTG even dur-
ing pregnancy ifwe evaluate the same efficacy in epi-
lepsy treatment with lesser teratogenic risk. Individual
approach to the woman with epilepsy and monother-
apy with minimal efficacious LTG dose with frequent
drug monitoring enlarges the possibility of successful
pregnancy. Taking into account all the possible risks
and complications during pregnancy in women with
epilepsy, the management of these women should
begin with pre-pregnancy counseling. Preconception
counseling and coordination among all members of
the health care team is a key to successful surveillance
Acta Clin Croat, Vol. 48, No.3, 2009
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of women with epilepsy of reproductive age. Planned
pregnancy enables proper periconceptional folic acid
supplementation and increases the likelihood of fa-
vorable outcome in women with epilepsy. No terato-
genicity was observed in this series of pregnancies.
Further follow up of their live births till school age
will be provided by neuropediatricians in order to as-
sess the potential long-term neurodevelopmental ef-
fect ofAED on the offspring.
Despite the small number of cases in the study,
these data indicate that treatment with LTG during
pregnancy might be relatively safe. Larger prospec-
tive studies are needed to obtain adequate power for
statistical analysis including large long-term cohort
studies.
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Sazetak
Surveillance of pregnancies on Iamotrtgtne
PROSPEKTIVNO PRACENJE TRUDNICA NA MONOTERAPIJI LAMOTRIGINOM U HRVATSKOJ-
PREDKONCEPCIJSKO SAVJETOVANJE I PRACENJE LIJEKOVA
s. Miskov, R. Gjergja-Juraski, Lj. Cvitanovii-Sojat, T Ivicevii Bakulii, A. FuCii, M. Bosnjalc-Pasi/, L Mikula i V Demarin
U ovoj studiji smo prospektivno pratili ishod trudnoce u 23 trudnice s epilepsijom koje su uzimale lamotrigin kao mo-
noterapiju. Trudnoca [e kod bolesnica rezultirala intrauterinom smrcu djeteta u jednom slucaju. spontanim abortusom u
jednom slucaju, te prijevremenim porodom u dva slucaja. Kod novorodencadi nisu zabiljezene kongenitalne malformacije.
Zene koje su planirale trudnocu i uzimale folnu kiselinu rodile su djecu s visom tjelesnom masom i visinom. Postojala je
velika razlicitost medu bolesnicama u pracenju doze lijeka te u potrebi za uskladivanjem doze. Veca je mogucnost uspjes-
nog planiranja trudnoce ako se svakoj bolesnici pristupi individualno uz minimalnu djelotvornu dozu lijeka (lamotrigin).
Lijecenje trudnica treba zapoceti savjetovanjem prije zaceca kada [e moguce i pravodobno zapoceti s uzimanjem folne ki-
seline. Unatoc malom broju slucajeva podaci iz nase studije pokazuju kako hjecenje lamotriginom tijekom trudnoce moze
biti relativno sigurno. Potrebne su vece prospektivne studije kako bi se postigla zadovoljavajuca statisticka snaga dobivenih
podataka.
Kljucne rijeci: Trudnoia - komplikaciJe; Trudnoia - terapiJaliJekovima; EpilepsiJa~ terapiJa liJekovima; Epilepsija - meta-
boiizam; Antikonvulzivi ~ krv
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